A First in Human Study of RT001 in Patients With Friedreich's Ataxia

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of RT001 in patients with Friedreich's ataxia.

Clinical Trial Description

Study RT001-002 is a randomized, double-blind, controlled, ascending dose study to evaluate the safety, tolerability, pharmacokinetic, disease state, and exploratory endpoints in patients with Friedreich's ataxia after oral administration. The study includes 2 dose levels of RT001. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02445794
Study type	Interventional
Source	Retrotope, Inc.
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	August 2015
Completion date	July 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02660112` - (+) Epicatechin to Treat Friedreich's Ataxia	Phase 2
Recruiting	`NCT02497534` - Biomarkers in Friedreich's Ataxia
Completed	`NCT04102501` - A Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Friedreich's Ataxia	Phase 3
Completed	`NCT01962363` - EPI-743 in Friedreich's Ataxia Point Mutations	Phase 2
Completed	`NCT02179333` - Preliminary Study of the Scale To Assess Ataxia and Neurologic Dysfunction (STAND)
Completed	`NCT01016366` - Safety Study of Carbamylated Erythropoietin to Treat Patients With the Neurodegenerative Disorder Friedreich's Ataxia	Phase 2
Recruiting	`NCT02069509` - Patient Registry of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS)
Terminated	`NCT00803868` - Pilot Study of Varenicline (Chantix®) in the Treatment of Friedreich's Ataxia	Phase 2/Phase 3
Completed	`NCT02797080` - Long-Term Safety Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia	Phase 3
Completed	`NCT02415127` - Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia	Phase 3
Completed	`NCT00897221` - A Study Investigating the Long-term Safety and Efficacy of Deferiprone in Patients With Friedreich's Ataxia	Phase 2
Completed	`NCT02840669` - A Study to Characterize the Cardiac Phenotype of Individuals With Friedreich's Ataxia (CARFA Study)	N/A
Completed	`NCT00697073` - Study to Assess the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients	Phase 3
Recruiting	`NCT02316314` - Characterization of the Cardiac Phenotype of Friedreich's Ataxia (FRDA)
Completed	`NCT00631202` - Efficacy of Epoetin Alfa in Patients With Friedreich's Ataxia	Phase 2
Completed	`NCT01728064` - Safety and Efficacy of EPI-743 in Patients With Friedreich's Ataxia	Phase 2
Completed	`NCT02593773` - Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study	Phase 3
Completed	`NCT01035671` - Safety and Efficacy Study of A0001 in Subjects With Friedreich's Ataxia	Phase 2
Completed	`NCT00811681` - Effect of Pioglitazone Administered to Patients With Friedreich's Ataxia: Proof of Concept	Phase 3
Completed	`NCT00537680` - Study to Assess the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia	Phase 3